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Background: We previously reported the clinical efficacy of adoptive immunotherapy (AIT) with dendritic
cells (DCs) pulsed with mucin 1 (MUC1) peptide and cytotoxic T lymphocytes (CTLs). We also reported that
gemcitabine (GEM) enhances anti-tumor immunity by suppressing regulatory T cells. Therefore, in the present
study, we performed combination therapy with AIT and GEM for patients with unresectable or recurrent
pancreatic cancer.
Patients and methods: Forty-two patients with unresectable or recurrent pancreatic cancer were treated. DCs
were generated by culture with granulocyte macrophage colony-stimulating factor and interleukin-4 and
then exposed to tumor necrosis factor-α. Mature DCs were transfected with MUC1-mRNA by electroporation
(MUC1-DCs). MUC1-CTLs were induced by co-culture with YPK-1, a human pancreatic cancer cell line, and
then with interleukin-2. Patients were treated with GEM, while MUC1-DCs were intradermally injected, and
MUC1-CTLs were intravenously administered.
Results: Median survival time (MST) was 13.9 months, and the 1-year survival rate was 51.1%. Of 42 patients, one
patient had complete response (2.4%), three patients had partial response (7.1%) and 22 patients had stable
disease (52.4%). The disease control ratio was 61.9%. The MST and 1-year survival rate of 35 patients who
received more than 1 × 107 MUC1-DCs per injection was 16.1 months and 60.3%, respectively. Liver metastasis
occurred in only 5 patients among 35 patients without liver metastasis before treatment. There were no severe
toxicities associated with AIT.
Conclusion: AIT with MUC1-DCs and MUC1-CTLs plus GEM may be a feasible and effective treatment for
pancreatic cancer.
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Pancreatic adenocarcinoma is the fourth leading cause
of cancer death worldwide and has an overall 5-year
survival rate of only 6% [1]. No adequate therapy for
pancreatic cancer has yet been found, and most patients
die within a year of diagnosis. New treatment strategies
are therefore necessary.
Immunotherapy has an advantage over radiation and
chemotherapies because it can act specifically against the
tumor without damaging normal tissue. Immunothera-
peutic approaches to pancreatic cancer have included the
use of monoclonal antibodies (mAbs) [2], cytokines [3],
vaccines [4], and lymphokine-activated killer (LAK)
cells [5]. Dendritic cells (DCs) play important roles as
antigen-presenting cells in innate and adaptive immunity
[6]. DC-based therapy has been used in clinical trials for
various cancers including pancreatic cancer [7-9].
Mucin 1 (MUC1) is overexpressed in an incompletely
glycosylated form in various human cancers [10]. We
have previously reported that the expression of MUC1
was observed in all cancer cells from all 55 pancreatic
ductal adenocarcinomas as well as 2 liver metastases by
immunohistochemistry. In contrast the expression of
MUC1 was not observed in specimens from normal
pancreas, chronic pancreatitis, or ductal hyperplasia of
the pancreas [11]. Cytotoxic T lymphocytes (CTLs)
recognize MUC1 molecules in a human leukocyte antigen
(HLA)-unrestricted manner, which means that these cells
can be used for all cancer patients such as pancreatic,
breast, or ovarian cancer expressing MUC1 antigen [12-16].
We have previously reported adoptive immunotherapy
(AIT) with CTLs stimulated by a MUC1-expressing human
pancreatic cancer cell line, YPK-1, (MUC1-CTLs) for
unresectable pancreatic cancer [15]. We have also re-
ported the efficacy of AIT with MUC1 peptide-pulsed
DCs and MUC1-CTLs [16].
DCs are potent antigen-presenting cells for induction
of primary T-cell dependent immune responses [6].
Numerous studies have demonstrated the feasibility of
DC-based immunization to induce host responses against
tumors [17]. DCs can be pulsed with peptide [16], full-
length protein [18], or whole tumor cells [19], and
transfected with DNA or RNA [20,21] or transduced
with recombinant viruses [22]. Comparative studies suggest
that mRNA transfection may be superior to other
antigen-loading techniques in generating immunocompe-
tent DCs [23].
Gemcitabine (GEM), which is a standard chemothera-
peutic agent for pancreatic cancer [24], is not immunosup-
pressive and may enhance responses to specific vaccines or
immunotherapy administered to activate or support im-
mune responses directed toward driving effector immunity
to cancer cells [24,25]. Treatment with GEM sensitizes hu-
man pancreatic carcinoma cell lines against CTL-mediatedlysis [26]. DC-based vaccination combined with GEM
increases survival in a murine pancreatic carcinoma
model [27].
To create a more effective therapy for pancreatic cancer,
we conducted combined AIT with MUC1-CTLs and
MUC1-mRNA–transfected dendritic cells (MUC1-DCs)
plus GEM.
Patients and methods
Patients and eligibility criteria
Between 2007 and 2012, 42 patients with unresectable or
recurrent pancreatic cancer histologically confirmed as in-
vasive ductal carcinoma by endoscopic ultrasound-guided
fine-needle aspiration were treated at the Department of
Digestive Surgery and Surgical Oncology (Department of
Surgery II) of the Yamaguchi University Graduate School
of Medicine. This therapy was not a clinical trial, but a
medical treatment approved as advanced health care by
the Japanese Ministry of Health, Labor and Welfare, and
provided for all patients who could pay the cost for this
therapy and who met the basic criteria as described below.
We retrospectively summarized safety and efficacy of this
therapy. The study protocol was also approved by the In-
stitutional Review Board for Human Use at the Yamaguchi
University School of Medicine. Written informed consent
was obtained from all patients.
Eligibility criteria were as follows: age of ≥20 years; life
expectancy ≥3 months; and adequate hepatic, renal, and
bone marrow function (serum creatinine level, <2.0 mg/dl;
bilirubin level, <3.0 g/dl; platelet count, ≥75,000/ml; total
white blood cell count ≥3,000/ml and ≤15,000/ml). All
patients had to have an Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of 0–2 at the
time of initial consultation.
Treatment protocol
Patients were treated with GEM (1000 mg/m2) for 3 weeks
(on days 1, 8, and 15) followed by 1 week of rest, while
MUC1-DCs suspended in 2 ml saline were injected intra-
dermally in the inguinal region as maximum available cell
products, and MUC1-CTLs suspended in 100 ml saline
were given intravenously as maximum available cell prod-
ucts on day 18 every 4 weeks (Figure 1a). This AIT was
repeated until progressive disease (PD) was recognized.
Adverse events and clinical responses
Adverse events were evaluated according to the Common
Terminology Criteria for Adverse Events v3.0 (CTCAE)
[28]. Computed tomography (CT) scan or magnetic res-
onance imaging (MRI) examination was made before the
treatment. Tumors were staged with the UICC classifica-
tion system.
CT or MRI was made after the first 3 transfers and was
repeated every 4 to 6 weeks after the treatment. Patients
Figure 1 Treatment regimen. a; Patients were treated with GEM (1000 mg/m2) for 3 weeks (on days 1, 8, and 15) followed by 1 week of rest,
while MUC1-DCs and MUC1-CTLs were administrated on day 18 every 4 weeks. b; MUC1-CTLs were induced by co-culture with YPK-1, a human
pancreatic cancer cell line, and then with IL-2. DCs were generated by culture with GM-CSF and IL-4 and then exposed to TNF-α. Mature DCs
were transfected with MUC1-mRNA by electroporation (MUC1-DCs).
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sponse Evaluation Criteria in Solid Tumors (RECIST)
Committee [29].
Generation of MUC1-mRNA
MUC1-mRNA was transcribed in vitro. An XhoI fragment
containing a full length of MUC1 cDNA was cloned into
the XhoI site of the pcDNA3.1. Clones containing the
MUC1 cDNA were isolated, and midi scale cDNA prepa-
rations were generated using Quantum Prep™ Plasmid
Midiprep Kit (Bio Rad, Hercules, CA, USA). The plasmid
vector was linearized with XhoI digest and purified with
Wizard SV Gel and PCR Clean-Up System (Promega,
Madison, Wisc., USA). In vitro transcription was then
carried out using a mMessage mMachine® T7 Ultra Kit
(Ambion, Austin, Tex., USA) according to the manufac-
turer’s protocol.
Separation of adherent and non-adherent cells
Peripheral blood mononuclear cells (PBMCs) were
harvested with the COBE Spectra Apheresis System
(COBE BCT, Inc., Lakewood, CO, USA). PBMCs from3000 ml of blood were enriched by density gradient
centrifugation with Ficoll-Paque (Amersham Pharmacia
Biotech, Uppsala, Sweden). The PBMCs were incubated
for 45 min in a 5% CO2 atmosphere at 37°C in serum-free
AIM-V medium (Gibco, Paisley, Scotland). Plastic-adherent
cells were used for the generation of DCs, while non-
adherent cells were used for the generation of CTLs.
Generation of MUC1-CTLs
MUC1-CTLs were induced as previously described [15].
Briefly, non-adherent cells were cultured in AIM-V with
the MUC1-expressing human pancreatic cancer cell line
YPK-1 (HLA-A2402) inactivated with 0.2 mg/ml mitomy-
cin C (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan). The
effector-to-stimulator cell ratio was 1,000:1. On days 3, 5,
and 7, recombinant human interleukin 2 (IL-2) (Shionogi
Pharmaceutical Co., Tokyo, Japan) was added to the cul-
tures at a final concentration of 10 units/ml (U/ml). The
plates were incubated in a 5% CO2 atmosphere at 37°C.
On day 10, MUC1-CTLs were washed 3 times with saline,
suspended in 100 ml saline and administered intraven-
ously (Figure 1b).
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cytotoxicity
Cytotoxicity assays of MUC1-CTLs induced from a
healthy volunteer with the HLA-A 24/26 were performed
as previously described (Additional file 1: Figure S1a) [15].
Briefly, target cells (1 × 106/ml) were labeled for 60 min at
37˚C with 100 μCi/ml radioactive sodium chromate (51Cr)
(Amersham Japan, Tokyo, Japan). The cells were then
washed 4 times in RPMI-1640 medium (Sigma-Aldrich).
Labeled cells were resuspended in culture medium
(1 × 105/ml). Effector cells consisting of induced MUC1-
CTLs were suspended at 0.5, 1.0 or 2.0 × 106/ml. Effector
cell suspension (0.1 ml) was added to a microplate (Falcon
Plastics, Cockeysville, MD) with 0.1 ml target cells, to
yield an effector to target cell ratio of 5:1, 10:1 or 20:1. All
experiments were performed in triplicate. Plates were in-
cubated for 4 h at 37˚C in a CO2 incubator. The amount
of 51Cr released into each well was determined with a γ
counter (Auto Well Gamma System ARC-202, Aloka,
Tokyo, Japan). The percentage of cytotoxicity was calcu-
lated as follows:
% cytotoxicity ¼ experimental release ‐ spontaneous release
maximum release ‐ spontaneous release
To measure the spontaneous 51Cr release of target
cells in the absence of effector cells, target cells were
mixed with 0.1 ml culture medium. To obtain maximal
a 51Cr release, target cells were treated with 0.1 ml
0.1 N hydrochloric acid [15].
Antibody inhibition assay of cytotoxicity of induced
MUC1-CTLs induced from a healthy volunteer with the
HLA-A 24/26 was described previously (Additional file 1:
Figure S1b) [15]. Briefly, anti-CD3, −CD4, −CD8 and anti-
class I mAbs (each diluted at 1:50) were used for blocking
assays and were purchased from Dako Corp., Carpinteria,
CA. The MUC1-expressing pancreatic cancer cell line
YPK-1 was used as the target cell. Effector cells consisting
of induced MUC1-CTLs were incubated with mAb at the
indicated concentrations for 45 min at 37˚C, washed 3
times in RPMI-1640 medium and suspended at 2 × 106/ml.
Target cells were labeled with 51Cr as described above,
washed 4 times and resuspended in culture medium
(1 × 105/ml). Effector cell suspension (0.1 ml) was added
with 0.1 ml target cells to yield a 20:1 effector to target
cell ratio for cytotoxicity assays as described above. For
anti-MUC1 mAb blocking, target cells were preincu-
bated for 1 h at 37˚C with anti-MUC1 mAb MY.1E12
(diluted at 1:200), kindly provided by Dr Tatsuo Irimura,
Department of Cancer Biology and Molecular Immun-
ology, Faculty of Pharmaceutical Sciences, University of
Tokyo, Japan. Cytotoxicity assays were performed as
described above [15].Generation of MUC1-DCs
Adherent cells were cultured in AIM-V medium contain-
ing 800 U/ml granulocyte macrophage colony-stimulat-
ing factor (GM-CSF) (Osteogenetics GmbH, Wurzburg,
Germany) and 500 U/ml IL-4 (Osteogenetics GmbH).
On days 3 and 6, GM-CSF and IL-4 were added to the
cultures at a final concentration of 400 U/ml and 250
U/ml respectively. On day 6, immature DCs (imDCs)
were cultured in AIM-V medium containing 1000 U/ml
tumor necrosis factor-α (TNF-α) (R&D Systems, Minne-
apolis, MN, USA). On day 10, floating and loosely adher-
ent cells were collected as mature DCs (mDCs). The
mDCs were washed once, suspended in AIM-V medium,
and adjusted to a final cell density of 2 × 106 cells/ml. Sub-
sequently, 400 μl of the cell suspension was mixed with
10 μg of MUC1-mRNA and electroporated in a 4-mm cu-
vette by using a BTX 830 square-wave electroporator
(Harvard Apparatus, Holliston, MA, USA). Electroporation
settings were adjusted to a single pulse, 400 V, 500 μs.
Subsequently, MUC1-DCs were washed 3 times with sa-
line, suspended in 2 ml saline and injected intradermally
in the inguinal region (Figure 1b).
Enhanced green fluorescent protein (EGFP) expression on
mDCs by flow cytometry
EGFP mRNA electroporated DCs were checked for EGFP
expression 18 h after transfection by an EPICS Flow
Cytometer. Gating was performed on cells exhibiting a
large forward scatter (FSC) and side scatter (SSC) pro-
file in order to allow exclusion of contaminating au-
tologous lymphocytes. Gated DCs were then evaluated
for EGFP expression. Non-transfected DCs were used
as a control.
Analysis of DC subsets
Induced DC subsets were analyzed with mAbs against
surface antigens. All mAbs were purchased from Coulter
(Hialeah, FL, USA). FITC-conjugated anti-CD80 (B7-1), −
CD83 (HB-15), −CD14 (B1), −HLA-ABC and –HLA-DR
(I2) were used. PE-conjugated anti-CD86 (B7-2) and -CD40
were also used according to the manufacturer's instructions.
Samples were analyzed with an EPICS Flow Cytometer
(Coulter Electronics, Inc., Hialeah, FL, USA) at a fluores-
cence excitation wavelength of 488 nm at 200–500 mW.
For each sample, 5,000 DCs were analyzed.
Analyses of Myeloid-derived suppressor cell (MDSC) and
regulatory T cell (Treg) in PBMCs
PBMCs (obtained before the treatment and one month
after 3 transfers) were enriched by density gradient
centrifugation with Ficoll-Paque (Amersham Pharmacia
Biotech, Uppsala, Sweden). Cells were aliquoted for MDSC
and Treg analysis. Cells were incubated with energy-
coupled dye-phycoerythrin-Texas Red (ECD)- conjugated
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CD25 (Beckman Coulter), VioBlue-conjugated anti-human
CD11b (M1/70.15.11.5) (Miltenyi Biotech, Bergisch
Gladbach, Germany), FITC-conjugated anti-human CD33
(HIM3-4) (eBioscience, San Diego, CA, USA) or the cor-
responding isotype control Abs (Beckman Coulter) for
30 min at 4°C. For Treg intra-nuclear Foxp3 analysis, after
treatment with rat serum and permeabilization buffer for
15 min at 4°C, cells were incubated with rat PE-labeled
human Foxp3 Ab (PCH101) (eBioscience, San Diego, CA,
USA) or the appropriate isotype control (Beckman
Coulter) for 30 min at 4°C, then washed, re-suspended
in 1% paraformaldehyde (PFA) in Dulbecco’s phosphate-
buffered saline (D-PBS) (Nissui pharmaceutical, Tokyo,
Japan), and stored at 4°C in the dark until flow cytomet-
ric analysis. Two-color flow cytometry was performed
with an EPICS flow cytometer (Coulter Electronics, Inc.,
Hialeah, FL). Treg analysis was performed using at least
30,000 cells that were gated in the region of the lymphocyte
population, whereas for MDSC analysis, all cells including
the region of mononuclear cells and the polymorpho-
nuclear leukocyte population were analyzed. Lympho-
cytes were gated in FSC and SSC profiles. Tregs were
identified as CD4 + CD25+ Foxp3+ and calculated as a
percentage of CD4+ lymphocytes. MDSCs were identified
as CD11b + CD33+ [30] and calculated as a percentage of
total PBMC.
Enzyme-linked immunoSpot (ELISPOT) assay
Frozen PBMCs, obtained before the treatment, after first
treatment and after third treatment, were thawed prior
to use and rested overnight in 10 U/ml benzonase nucle-
ase (Novagen) at 37°C 5% CO2 in a humidified incubator,
and then used in the next step. PBMCs (responder cells)
were cultured with the MUC1-mRNA electroporated
PBMCs (stimulator cells) at the responder cells to stimula-
tor cells (R/S ratio) of 1:1, and then were measured for
interferon-γ (IFN-γ) responses using ex vivo ELISPOT
assay. Nitrocellulose bottomed 96-well Multiscreen plates
(Millipore, UK Ltd) were coated with anti-human-IFN-γ
mAb (Mabtech, UK) overnight at 4°C. PBMCs were plated
in 100 μl final volume and plates were incubated for
18–20 h in a 5% CO2 atmosphere at 37°C. Assays were
performed in triplicate and the results were averaged.
Plates were washed and developed. Number of spots on
the plate was counted by Eliphoto Scan (Minerva Tech,
Tokyo, Japan). MUC1 specific spots of IFN-γ were counted
and calculated as described below.
MUC1 specific spots ¼ Number of spots from Að Þ
‐ Number of spots from Bð Þ
A; PBMCs co-cultured with PBMCs electroporated with
MUC1 mRNAB; PBMCs co-cultured with PBMCs electroporated
without mRNA
Evaluation of DC migration
Indium oxine (111In-Oxine) labeled DC study was per-
formed in one patient with stable disease (SD). DCs were
labeled according to the protocols supplied by the manufac-
turer (Nihon Medi-Physics, Hyogo, Japan). Mature-DCs
were resuspended in platelet-poor autologous plasma
(CFP1) and incubated for 15 min at room temperature with
radioactive 111In-Oxine (1 mCi) (Nyconmed Amersham
Inc., Buckinghamshire, UK). After two washes to eliminate
the unbound isotope, the cells were resuspended in a total
volume of 1.5 ml of CFP1. Radiolabelling of the DCs and
culture supernatant was evaluated with a gamma camera,
after which DCs were intradermally inoculated 10 cm from
inguinal lymph nodes. Scintigraphic images of the depot
were acquired with a gamma camera 0, 2, 24, and 48 h after
injection.
Statistical analysis
Results are expressed as means ± standard error (SE). All
data were analyzed by using GraphPad Prism V5.0
(GraphPad Software, Inc., San Diego, CA). Changes in
surface markers were assessed with the paired Student’s t
test. Survival curves were analyzed by the Kaplan-Meier
method and the log-rank test. Categorical variables were
compared by using Chi-square and Fisher’s exact test.
P-values <0.05 were considered statistically significant.
Results
Clinical outcomes
Patient characteristics and clinical outcomes are sum-
marized in Table 1. Of 42 patients receiving AIT with
MUC1-DCs and MUC1-CTLs plus GEM, 1 patient with
recurrence had complete response (CR) (2.4%), 3 patients
with stage III (n = 1) and stage IV (n = 2) had partial re-
sponse (PR) (7.1%), 22 patients with stage III (n = 11),
stage IV (n = 7) and recurrence (n = 4) had SD (52.4%),
and 16 patients with stage III (n = 2), stage IV (n = 10) and
recurrence (n = 4) had PD (38.1%). The disease control
rate was 61.9%.
Images from gadolinium ethoxybenzyl diethylenetria-
mine pentaacetic acid-enhanced (Gd-EOB-DTPA) MRI
and CT scans of a patient with CR are shown in Figure 2.
He had liver metastasis after curative surgery (Figure 2a
and b). After 3 transfers, liver metastasis disappeared
completely (Figure 2c and d). In contrast, the other 6
patients who had liver metastasis before this therapy had
PD and the median survival time (MST) was 6.3 months
(data not shown).
The 1-year survival rate was 51.1%, and the MST was
13.9 months in all patients (Figure 3a). Liver metastasis
during therapy appeared in only 5 of 35 patients without
Table 1 Patient characteristics and clinical outcomes





















Number of CTLs (×108/time)
Mean 6.3
Range 1.0-12.4













HLA; human leukocyte antigen, CTL; cytotoxic T lymphocyte,DC; dendritic cell,
CR; complete response, PR; partial response,SD; stable disease, PD;
progressive disease.
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rate and MST in 35 patients who received more than
1 × 107 MUC1-DCs per injection were significantly better
than for 7 patients who received less than 1 × 107cells
(60.3% vs. 0%, 16.1 months vs. 6.2 months, p = 0.0036)
(Figure 3b). Administration times and total number ofMUC1-CTLs and MUC1-DCs were 6.2 ± 0.8 times, 4.5 ±
0.7 × 109 cells and 12.9 ± 1.8 × 107 cells in the high dose
group, and 3.1 ± 0.2 times, 1.5 ± 0.2 × 109 cells and 1.9 ±
0.5 × 107 cells in the low dose group. The 1-year survival
rate and MST in 36 patients who received more than
3 × 108 MUC1-CTLs per injection were significantly
better than for 6 patients who received less than 3 × 108
cells (56.6% vs. 16.7%, 15.1 months vs. 5.2 months, p =
0.0060) (Figure 3c). Administration times and total num-
ber of MUC1-CTLs and MUC1-DCs were 6.3 ± 0.8 times,
4.6 ± 0.7 × 109 cells and 12.4 ± 1.8 × 107 cells in the high
dose group, and 2.3 ± 0.3 times, 0.5 ± 0.1 × 109 cells and
2.4 ± 0.5 × 107 cells in the low dose group. The 1-year sur-
vival rate and MST in 30 patients who received both more
than 1 × 107MUC1-DCs per injection and 3 × 108 MUC1-
CTLs per injection were significantly better than for the
other 12 patients (66.7% vs. 10.4%, 16.5 months vs.
5.7 months, p = 0.0002) (Figure 3d). Administration times
and total number of MUC1-CTLs and MUC1-DCs were
6.8 ± 0.9 times, 5.0 ± 0.8 × 109 cells and 14.4 ± 2.0 × 107
cells in the high dose group, and 2.9 ± 0.3 times, 1.3 ±
0.3 × 109 cells and 2.5 ± 0.5 × 107 cells in the low dose
group. There was no significant bias of patient characteris-
tics between the high dose group and low dose group
(Table 2).
A comparative analysis revealed that there were no sig-
nificant differences between the clinically good (CR/PR/SD)
and poor responders (PD) for age, sex, disease stage
and neutrophil/lymphocyte ratio, except for pretreat-
ment liver metastasis (p = 0.0081) and the number of
DCs (p = 0.0015). The number of CTLs per injection
was trend to higher in the clinically good responders
(p = 0.0537) (Table 3).Safety and toxicity
The major grade 3 and 4 adverse events are summarized
in Table 4. The most common grade 3or 4 hematologic
adverse event was neutrophils (31%). Grade 3 or 4 an-
orexia (14.3%) was the most nonhematologic adverse
event. No AIT-related adverse events such as rash, fever,
chill, and injection site reaction were observed. There
was no clinical or radiological evidence of autoimmune
reaction in any of the patients.Cytotoxic activity of induced MUC1-CTLs and antibody
inhibition of cytotoxicity
Induced MUC1-CTLs (HLA-A24/26) showed strong
cytotoxicity against pancreatic cancer cell lines (YPK-1;
HLA-A24, and YPK-3; HLA-A02) which expressed MUC1
antigen on the cell surface in an HLA- unrestricted man-
ner. However, cytotoxicity against the esophageal cancer
cell lines (YES-1 and −2), which did not express MUC1,
was low (Additional file 1: Figure S1a).
Figure 2 MRI (Gd-EOB-DTPA MRI, hepatobiliary phase) and CT scans of a patient with CR. Monitoring of in vivo migration of
111In-oxine labeled dendritic cells with scintigraphy. MRI and CT scans revealed a liver metastatic lesion (arrow) (a, b). After 3 cell transfers,
the metastatic lesion disappeared completely (c, d). (a, c): MRI. (b,d): CT. Two hours after injection, DCs migrated from the injection site to inguinal
lymph nodes (arrowhead) (e). Forty-eight hours after injection, that accumulation extended into distant lymph node, but still remained in the
injection site (arrow) and inguinal lymph nodes (f).
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toxicity against YPK-1 cells. Anti-MUC1 mAb also inhib-
ited cytotoxicity in these cells. Anti-class I mAb showed
no inhibition of CTL cytotoxicity (E:T = 20:1; anti-CD3,
66.5%; −CD4, 26.9%; −CD8, 76.9%; anti-class I, 11.8% and
anti-MUC1, 64.1%) (Additional file 1: Figure S1b) [15].
These results showed that cytotoxicity of induced MUC1-
CTLs was MUC1 specific and HLA-unrestricted.
EGFP expression in EGFP mRNA electroporated DCs
To confirm the translation efficiency from introduced
mRNA to protein, the mDCs were electroporated with
EGFP mRNA. The expression coefficient of EGFP was
more than 95% (Figure 4a). This result indicates that DCs
can translate the introduced mRNAs to encoded protein.
Profiles of surface markers of induced DCs
A comparison of surface marker expression between
imDCs and mDCs was shown (Figure 4c). Twenty ninepatients were evaluable. The expression of each antigen
in imDCs was found in 17.5 ± 2.9% (CD80), 67.1 ± 3.1%
(CD86), 2.8 ± 0.7% (CD83), 92.6 ± 1.7% (CD40), 9.5 ± 2.3%
(CD14), 98.6 ± 0.3% (HLA-ABC) and 92.8 ± 1.8% (HLA-
DR). The expression of each antigen in mDCs was found
in 92.1 ± 1.5% (CD80), 96.5 ± 0.7% (CD86), 75.6 ± 3.3%
(CD83), 98.9 ± 0.5% (CD40), 4.6 ± 3.4% (CD14), 99.4 ±
0.2% (HLA-ABC) and 96.6 ± 1.1% (HLA-DR). The percent-
age of CD80+, CD83+, and CD86+ DCs was extremely in-
creased in mDCs as compared with imDCs (P < 0.0001). A
high expression level of CD40 was also observed in mDCs
(P = 0.0004). HLA-class I and HLA-class II expression
levels were identical between imDCs and mDCs.
Change of CD11b + CD33+ cells and CD4+ CD25+ Foxp3+
cells in PBMCs
We assessed negative immune factors focusing on
CD11b + CD33+ cells (n = 14) and CD4+ CD25+ Foxp3+
cells (n = 18) in PBMCs before and one month after 3
Figure 3 Overall survival rates in patients with advanced pancreatic cancer treated by AIT with MUC1-DCs and MUC1-CTLs plus GEM.
a; MST was 13.9 months, and the 1-year survival rate was 51.1% in all 42 patients. b; 35 patients who received more than 1 × 107MUC1-DCs per
injection (MST, 16.1 months) vs. 7 patients who received less than 1 × 107cells (MST, 6.2 months), p = 0.0036. c; 36 patients who received more than
3 × 108 MUC1-CTLs per injection (MST, 15.1 months) vs. 6 patients who received less than 3 × 108 (MST, 5.2 months), p = 0.0060. d; 30 patients who
received both more than 1 × 107MUC1-DCs per injection and 3 × 108 MUC1-CTLs per injection (MST, 16.5 months) vs. the other 12 patients (MST,
5.7 months), p = 0.00020.
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http://www.translational-medicine.com/content/12/1/175transfer. Before treatment there was no difference in the
percentage of CD11b + CD33+ cells between patients with
CR, PR, and SD (15.1 ± 2.2, n = 11) and patients with PD
(17.8 ± 3.9, n = 3). After treatment, the percentage of
CD11b + CD33+ cells in patients with CR, PR and SD
(10.2 ± 1.6) was significantly lower than patients with PD
(21.9 ± 4.0) (p = 0.0430) (Figure 5b). Before treatment
there was no difference in the percentage of CD4+
CD25+ Foxp3+ cells between patients with CR, PR and
SD (0.68 ± 0.20, n = 14) and patients with PD (1.03 ±
0.62, n = 4). After treatment, the percentage of CD4+
CD25+ Foxp3+ cells in patients with CR, PR and SDTable 2 Patient characteristics between the high dose group
DC
High dose group Low dose group








DC; dendritic cell, CTL; cytotoxic T lymphocyte.(0.57 ± 0.18) was significantly lower than patients with
PD (1.33 ± 0.41) (p = 0.0495) (Figure 5f ).
ELISPOT analysis
IFN-γ ELISPOT assay was performed to evaluate the
specific responses to MUC1 of immune effector cells from
6 patients. The number of MUC1 specific spots was 6.8 ±
2.3, 13.1 ± 5.8 and 23.2 ± 13.9, prior to treatment, after
first treatment and after third treatment, respectively.
More IFN-γ spots were observed in post-treatment
compared with pretreatment PBMC samples. Although
IFN-γ activity was increased in this assay, it was stilland low dose group
CTL
p-value High dose group Low dose group p-value
(n = 36) (n = 6)




p = 0.5788 p = 1.000
30 5
6 1
Table 3 Comparison between the clinically good and poor responders
Characteristics Clinically good (CR/PR/SD) Clinically poor (PD) p-value
Number of patients 26 16
Age (years) 61.6 (37-81) 65.6 (43-81) p = 0.2434
Sex p = 0.7513
Males 12 9
Females 14 7




Liver metastasis (pretreatment) p = 0.0081
Absence 25 10
Presence 1 6
NLR 2.3 (0.7-6.4) 3.1 (0.4-6.1) p = 0.1364
Number of CTLs (x108/time) 7.0 (2.8-12.4) 5.1 (1.0-9.0) p = 0.0537
Number of DCs (x107/time) 2.1 (0.9-3.9) 1.2 (0.04-2.9) p = 0.0015
CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease NLR; neutrophil/lymphocyte ratio, CTL; cytotoxic T lymphocyte,
DC; dendritic cell.
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NK cells (Figure 6).Monitoring of in vivo migration of 111Indium (In)-oxine
labeled dendritic cells with scintigraphy
Scintigraphic images obtained from one patient 2 h and
48 h after DC administration demonstrated that 111In-oxine
labeled DCs accumulated at the injection site and regional
lymph nodes 2 h after injection. Forty-eight hours after
injection, the accumulation extended into distant lymph
nodes, but still remained in the injection site and regional
lymph node (Figure 2e and f).Table 4 Grade 3 and 4 Adverse Events in 42 patients













AST; aspartate aminotransferase, ALT; alanine aminotransferase.Discussion
In the present study, adoptive immunotherapy (AIT)
with MUC1-DCs and MUC1-CTLs plus GEM resulted
in a 1-year survival rate of greater than 50% in patients
with unresectable or recurrent pancreatic invasive ductal
carcinoma (Figure 3a). One patient, who had liver me-
tastasis after curative surgery, had CR (Figure 2a to d).
Three patients had PR, and one of these patients had
curative surgery 12 months after this therapy. Although
it have been reported that 73% of patients who died from
pancreatic cancer were found to present with liver metasta-
ses at autopsy [31], in this therapy liver metastasis appeared
in only 5 patients (14%) among 35 patients without liver
metastasis before treatment. We observed no severe
adverse events related to our AIT (Table 4).
MST following GEM monotherapy, which is the stand-
ard chemotherapy for unresectable pancreatic cancer, was
5.7 months, and the 1-year survival rate was 18% [24]. Al-
though some trials of combination therapies including
GEM and other cytotoxic agents resulted in improved re-
sponse rates over GEM alone, they failed to show survival
benefits [32-34]. The combination of erlotinib plus GEM
showed a significant improvement in overall survival;
however, the increase in MST was marginal (6.24 vs.
5.91 months) [35]. In another study, MST was 11.1 months
for the FOLFIRINOX group, compared with 6.8 months
in the GEM group, showing a significant difference.
However, markedly more adverse events were noted in
the FOLFIRINOX group [36]. Since these outcomes in
advanced pancreatic cancer are still poor, more effective
treatment strategies are required.
Figure 4 Flow cytometric analysis of DCs. EGFP expression was analyzed by flow cytometry 18 h post-transfection. a; The expression level of
EGFP was more than 95%. b; As a control non-transfected DC were used. c; Expression of DC surface markers was evaluated by flow cytometry.
Twenty nine patients were evaluable. Comparative data were shown in histograms for immature (dotted line) and mature (solid line) DCs. The
expression of each antigen in imDCs was found in 17.5 ± 2.9% (CD80), 67.1 ± 3.1% (CD86), 2.8 ± 0.7% (CD83), 92.6 ± 1.7% (CD40), 9.5 ± 2.3% (CD14),
98.6 ± 0.3% (HLA-ABC) and 92.8 ± 1.8% (HLA-DR). The expression of each antigen in mDCs was found in 92.1 ± 1.5% (CD80), 96.5 ± 0.7% (CD86),
75.6 ± 3.3% (CD83), 98.9 ± 0.5% (CD40), 4.6 ± 3.4% (CD14), 99.4 ± 0.2% (HLA-ABC) and 96.6 ± 1.1% (HLA-DR). *p = 0.0004, **p < 0.0001.
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peptide [16]. In this study, mDCs were transfected with
MUC1-mRNA by electroporation, because antigen epi-
topes are naturally processed, and a variety of different
epitopes are long term presented by both HLA class I
and class II molecules. It has been reported the advantage
of endogenous expression by DC is that T cell epitopes do
not need to be specified, HLA type is not a limiting factor
and multiple epitopes (both CTL and helper T cell epi-
topes) can be presented [37]. In our previous therapy
(MUC1 peptide-pulsed DCs and MUC1-CTLs), the MST
was 9.8 months [16]; in the present study, the MST was
13.9 months. The improved survival benefit of the present
study may be related to patient characteristics such as dis-
tant metastasis, the GEM combination, or MUC1 mRNA
transfection. Distant metastasis such as liver metastasis,
lung metastasis or peritoneal dissemination was present in15 of 20 (75%) previous patients and 28 of 42 (66.7%)
present patients, which is no significant difference.
GEM has the potential to augment the antitumor effects
of cancer immunotherapy by suppressing Treg induction
[25,38], and also reduces MDSC [39], but does not reduce
CD4+ T cells, CD8+ T cells, NK cells, macrophages, or B
cells [40]. We therefore performed a combination therapy
with AIT and GEM. In the present study, we observed
a significant decrease in the percentages of MDSC
(Figure 5b, p = 0.043) and Treg (Figure 5f, p = 0.0495)
in patients with CR, PR and SD when compared with
those in patients with PD. Hence, we speculated that
clinical benefit may be related to the reductions of
MDSC and Treg.
A survival and clinical benefit was shown in the patients
who received high dose MUC1-DCs and MUC1-CTLs
per injection (Figure 2b to 3d, Table 3). Administration of
Figure 5 Frequency of CD11b + CD33+ cells and CD4 + CD25 + Foxp3+ cells in the PBMCs. a; Analysis for CD11b as well as CD33
expression by flow cytometry. b; The percentage of CD11b + CD33+ cells of patients with CR, PR and SD (n = 11) (solid line) and PD (n = 3)
(dashed line) was measured. *p = 0.043. c; Lymphocytes were identified based on their characteristic properties shown in the FSC and SSC. d; A
representative gating was set for CD4+ cells from lymphocytes. e; Analysis for CD25 as well as Foxp3 expression in the CD4+ lymphocytes gate.
f; The percentage of CD4+ CD25 + Foxp3+ cells of patients with CR, PR and SD (n = 14) (solid line) and PD (n = 4) (dashed line) was measured. * p = 0.0495.
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achieve a clinical effect. Induction of CTLs in patients
with advanced pancreatic cancer may be suppressed by ac-
tivated granulocytes and MDSC [41]. We have reported
that pancreatic cancer patients had low CTL precursors
reactive to EBV peptide as compared with healthy volun-
teers [4]. This result suggests that the cellular immunity of
these patients might be depressed, and therefore other
supportive immunotherapies may be needed for these pa-
tients to increase their general level of immunity prior to
specific immunotherapy.
The migration of DC is an important question that
needs to be addressed in clinical therapy. A key stepinvolved with T cell sensitization after administration
is DC migration into regional draining lymph nodes and
antigen presentation to lymphocytes. In the present study,
the induction of mDCs was performed successfully, which
was demonstrated by the high expression of CD83 (75.6 ±
3.3%, Figure 4c) that expressed at activated and mDCs
[42]. It has been reported that a better migration activity
is obtained using intradermal route than subcutaneous
routes and that mDCs show higher migration than imDCs
[43,44]. We confirmed the migration of administered
mDCs by scintigraphic images collected 2 and 48 h after
injection in one patient. Two hours after injection, mDCs
migrated from the injection site to inguinal lymph nodes.
Figure 6 Representative immunologic monitoring assays detecting antigen-specific responses induced IFN-γ producing cells. a; IFN-γ
producing cells were increased in PBMCs co-cultured with PBMCs electroporated with MUC1 mRNA compared with PBMCs co-cultured with
PBMCs electroporated without MUC1 mRNA. b; Six patients were evaluable. More MUC1 specific spots were observed in post-treatment compared
with pretreatment PBMC samples.
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extended into distant lymph node, but still remained
in the injection site as well as inguinal lymph nodes
(Figure 2e and f ).
In conclusion, our cancer immunotherapy in com-
bination with GEM was safe and appears to be effective
for the patients with unresectable pancreatic cancer.
Although we need to verify this preliminary result by a
much larger prospective randomized study, we believe
that these findings surely lead to the novel therapeutic
strategy for advanced pancreatic cancer.
Conclusions
We retrospectively analyzed the outcome of 42 patients
with unresectable or recurrent pancreatic cancer treated
with MUC1-DCs (MUC1-mRNA transfected DCs) and
MUC1-CTLs (lymphocytes stimulated by co-culture with
a MUC1 expressing human pancreatic cancer cell line and
IL-2). Our adoptive immunotherapy was safe and effective
in a subgroup with sufficient induction of DCs and CTLs.
Further randomized control studies of large numbers ofpatients are needed to confirm the efficacy of this combin-
ation therapy for unresectable pancreatic cancer.
Additional file
Additional file 1: Figure S1. Cytotoxicity of induced MUC1-CTLs and
antibody inhibition of cytotoxicity. (a) CTLs were stimulated by the
MUC1-expressing human pancreatic cancer cell line, YPK-1 (HLA-A 2402,
MUC1-positive). Target cell lines were YPK-1, YPK-3 (pancreatic cancer,
HLA-A 0201, MUC1-positive), YES-2 (esophageal cancer, HLA-A 2404,
MUC1-negative) and YES-1 (esophageal cancer, HLA-A 0201, MUC1-negative).
Induced CTLs were cytotoxic against MUC1-expressing pancreatic cancer
cell lines regardless of the HLA-A phenotype. Low cytotoxicity was observed
in MUC1-negative esophageal cancer cell lines. Cytotoxicity was MHC
unrestricted and clearly decreased with the decreasing effector cell number.
(b) Anti-CD3 or -CD8 mAb strongly inhibited cytotoxicity against YPK-1cells,
whereas anti-class I mAb showed no inhibition. YPK-1 cells treated with
anti-MUC1 mAb also showed a low cytotoxicity.
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